X
[{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Shanghai Henlius Biotech Says Entered Cooperation Agreement With Sanyou Biopharmaceuticals & Shanghai Zj Bio-Tech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanyou Bio Congratulates Dragon Boat Pharmaceutical on the Approval of Clinical Trials of anti-CLDN18.2 Antibody Drug BC008","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Dragon Sail Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Biopharmaceuticals Forged Strategic Partnership with Dragon Sail Pharmaceutical to Upgrade Integrated Innovative Antibody Drug R&D","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sinorda Biomedicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Biopharmaceuticals and Sinorda Biomedicine Signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Sanyou Biopharmaceuticals
Filters
Companies By Therapeutic Area
Details:
The agreement aims to advance the innovative bispecific antibody drug project by leveraging Sanyou's world-leading core technology platform for integrated R&D and preclinical development and Sinorda's rich experience in preclinical and clinical oncology immunotherapy.
Lead Product(s):
Bispecific Antibody
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Sinorda Biomedicine
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
August 22, 2023
Details:
Under the agreement, the companies will develop therapeutic biological products in the therapeutic area of oncology through Sanyou's world-leading core technology platform.
Lead Product(s):
Biological Product
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Hangzhou Zhongmei Huadong Pharmaceutical
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
June 28, 2023
Details:
Sanyou will provide preclinical R&D services including drug screening, pharmacology research, process development and quality control of various biological drugs including monoclonal antibodies, multi-specific antibodies, ADC drugs, etc.
Lead Product(s):
Antibody
Therapeutic Area: Technology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Dragon Sail Pharmaceutical
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
June 20, 2022
Details:
Preclinical study data of BC008 antibody injection showed drug can specifically target and bind CLDN18.2 molecules on cell surface, and play an anti-tumor role by specifically killing CLDN18.2-positive tumor cells through Fc-mediated immune effector functions.
Lead Product(s):
BC008
Therapeutic Area: Oncology
Product Name: BC008
Highest Development Status: IND Enabling
Product Type: Large molecule
Recipient:
Dragon Boat Pharmaceutical
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 20, 2022
Details:
Agreement aims to develop fully human antibody drug for covid-19 for monotherapy or combination treatment of covid-19.
Lead Product(s):
Antibody drug conjugate
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Shanghai Henlius Biotech
Deal Size: $3.5 million
Upfront Cash: Undisclosed
Deal Type: Agreement
May 06, 2020